Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
22-25 March, 2025
Not Confirmed
Not Confirmed
23-24 March, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
22-25 March, 2025
Industry Trade Show
Not Confirmed
23-24 March, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
15 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/natural-complex-by-pharmactive-biotech-demonstrates-capabilities-to-support-prostate-and-bladder-health-consumer-study-indicates-302276172.html
19 May 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/05/19/2447129/0/en/Annual-General-Meeting-of-Active-Biotech-AB.html
28 Apr 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/04/28/2430974/0/en/Annual-Report-2021-Active-Biotech-AB-publ.html
25 Apr 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/04/26/2428706/0/en/Active-Biotech-strengthens-the-patent-protection-for-laquinimod-in-eye-disorders.html
21 Apr 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/04/21/2426095/0/en/Active-Biotech-Interim-Report-Q1-2022.html
20 Apr 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/04/20/2425657/0/en/Active-Biotech-NOTICE-OF-ANNUAL-GENERAL-MEETING-OF-SHAREHOLDERS.html
Details:
Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.
Lead Product(s): Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area: Oncology Brand Name: ABR-215050
Study Phase: Phase IProduct Type: Small molecule
Recipient: Wistar Institute of Anatomy and Biology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 22, 2024
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Wistar Institute of Anatomy and Biology
Deal Size : Undisclosed
Deal Type : Acquisition
Active Biotech Acquires Exclusive Rights to Patents of Tasquinimod in Combination Therapy
Details : Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.
Product Name : ABR-215050
Product Type : Small molecule
Upfront Cash : Undisclosed
May 22, 2024
Details:
Laquinimod is a first-in-class immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment.
Lead Product(s): Laquinimod
Therapeutic Area: Ophthalmology Brand Name: TV-5600
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Active Biotech Strengthens the Patent Protection for Laquinimod in Eye Disorders
Details : Laquinimod is a first-in-class immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment.
Product Name : TV-5600
Product Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2022
Details:
Under the terms of the agreement, Oncode Institute, a foundation under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum, grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Active Biotech.
Lead Product(s): Tasquinimod
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Oncode Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 09, 2022
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Oncode Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Oncode Institute, a foundation under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum, grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Ac...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
February 09, 2022
Details:
Preclinical data on drug tasquinimod, a small molecule immunomodulator Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.
Lead Product(s): Tasquinimod
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Lead Product(s) : Tasquinimod
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Preclinical Tasquinimod Data Presented at ASH 2021 Available on Active Biotech’s Website
Details : Preclinical data on drug tasquinimod, a small molecule immunomodulator Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2021
Details:
A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.
Lead Product(s): Laquinimod
Therapeutic Area: Ophthalmology Brand Name: ABR-215062
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2021
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod
Details : A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.
Product Name : ABR-215062
Product Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2021
Details:
Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.
Lead Product(s): Naptumomab Estafenatox,Durvalumab
Therapeutic Area: Oncology Brand Name: ABR-217620
Study Phase: Phase IProduct Type: Antibody-drug Conjugate
Sponsor: NeoTX Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2021
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Data on Naptumomab Estafenatox Enhancing CAR-T Cells Potency Presented by Active Biotech’s Partn...
Details : Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
November 30, 2021
Details:
Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.
Lead Product(s): Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2021
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Active Biotech: Tasquinimod Clinical Development in Multiple Myeloma Advances Into Combination Th...
Details : Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2021
Details:
The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.
Lead Product(s): Naptumomab Estafenatox,Durvalumab
Therapeutic Area: Oncology Brand Name: ABR-217620
Study Phase: Phase I/ Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: NeoTX Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 05, 2021
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : NeoTX Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Active Biotech Provides Status Update of its Clinical Naptumomab Project
Details : The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 05, 2021
Details:
Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.
Lead Product(s): Laquinimod
Therapeutic Area: Ophthalmology Brand Name: ABR-215062
Study Phase: Phase IProduct Type: Small molecule
Recipient: Famar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 04, 2021
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Recipient : Famar
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.
Product Name : ABR-215062
Product Type : Small molecule
Upfront Cash : Undisclosed
February 04, 2021
Details:
In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.
Lead Product(s): Naptumomab Estafenatox,Durvalumab
Therapeutic Area: Oncology Brand Name: ABR-217620
Study Phase: Phase IProduct Type: Antibody-drug Conjugate
Sponsor: NeoTX Therapeutics
Deal Size: $71.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 11, 2020
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : NeoTX Therapeutics
Deal Size : $71.0 million
Deal Type : Licensing Agreement
Active Biotech Receive Milestone Payment From Neotx
Details : In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
December 11, 2020
ABOUT THIS PAGE
Active Biotech is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Tasquinimod bulk with DMF offered by Active Biotech